Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring material items (adjusted EBITDA).  

The following tables detail the reconciliation of non-GAAP to GAAP financial metrics:

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA(in millions)(unaudited)Three Months EndedJune 30, Six Months EndedJune 30, Year EndingDecember 31, 2011 NOTES2011201020112010Guidance GAAP Net Income (Loss)$ (5.1)$ (0.5)$ (9.4)$   0.7 $(43) - $(33) Interest expense, net1.3

1.6

2.6

2.8

6Income tax expense3.9

1.1

8.7

1.7

14Depreciation6.3

4.4

12.7

8.4

25Amortization1.0

0.9

1.9

1.0

4EBITDA 7.47.516.514.6 6 - 16 Stock-based compensation10.6

9.2

21.0

17.7

45Gain on sale of equity investments-(0.9)

-Contingent consideration

(1)

(4.1)

0.8

(4.6)

1.5

(2)Adjusted EBITDA$ 13.9$ 17.5$ 32.9$ 32.9 $49 - $59 (1)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses th
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... ... 04, 2015 , ... San Francisco cosmetic dentist , ... is a newer method for creating restorations through innovative imaging equipment and on-site ... need for multiple appointments, CEREC produces restorations with total precision for a natural ...
(Date:9/4/2015)... ... 04, 2015 , ... Bio-Logic Aqua® Research, a fresh water ... only mission and research focus: Water Life Science®. In the current warming and ... is becoming dangerously accelerated. As a result of the global fresh water, water ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... its first neighborhood created specifically for adults with intellectual, developmental and acquired disabilities. ... area and feature 30 cottage or “pocket” homes. In this community, adults will ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what he ... the Vatican and society is. Yisrayl also provides the meaning of his own name and ...
(Date:9/3/2015)... ... September 04, 2015 , ... AlignLife of Wauwatosa is excited to ... so many children and adults who don't have the ability to buy a jacket ... holding our annual Coat Drive to help those in need." , This is AlignLife's ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... , A nano-sensor for better detection of Mad Cow ... advance in food safety, researchers in New York are ... low levels of the deadly prion proteins that cause ... sensor, which detects binding of prion proteins by detecting ...
... JOSE, Calif., March 3 Interwoven, Inc.,(Nasdaq: ... solutions, today,announced that it will present a joint ... the 2008 AIIM International Exposition and Conference,on March ... & Exhibition Center., (Logo: http://www.newscom.com/cgi-bin/prnh/20071205/INTWOVLOGO ), ...
... The Quigley,Corporation (Nasdaq: QGLY ) today reported net ... 31, 2007, compared to $14.2 million,reported for the same ... 2007,net sales were $39.5 million compared to $42.1 million ... quarter ended December 31, 2007 reflects a net sales,decrease ...
... to treat their diabetes ... and out, PRINCETON, N.J., March 3 Novo Nordisk, a,world ... program is back for a third year of providing free diabetes,education ... by,diabetes. This dynamic outreach kicks off in New York City, where ...
... Will Conduct, Webcast For Pet Owners, Covering ... March 3 Morris Animal Foundation (MAF) will,sponsor a ... their pets on,March 13, 2008, from 8:00 p.m. to ... all aspects of pain management, including common,causes of pain, ...
... Beauty Get a New Jolt with Java, ... destination that helps solve people,s everyday problems by,providing ... the,world,s most popular bean by providing interesting facts ... Awareness Month" in March.,HowToDoThings.com has created a Caffeine ...
Cached Medicine News:Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 2Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 3Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 4Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 5Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 6Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 7Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 8Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 9Health News:Blue Cross Blue Shield of Massachusetts and Interwoven to Present at 2008 AIIM International Exposition and Conference 2Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 2Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 3Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 4Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 5Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 6Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 7Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 8Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 2Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 3Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 4Health News:Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation 2Health News:HowToDoThings.com Brews Up New Uses for Coffee That Will Perk You Up in Recognition of March's 'Caffeine Awareness Month' 2
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
... up of doublet objective and high power ... and 3.0x. The true benefit of this ... maintaining focal clarity is made possible due ... ultra lightweight aluminum bar and individual interpupillary ...
... Left. 23 gauge thin wall ... Angled 20 degree shaft 10 mm ... set 0.5 mm behind aspiration tip. ... 46 cm (18.1 inches) of silicone ...
Medicine Products: